These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 14609347)

  • 1. Drug therapy for adults with attention-deficit hyperactivity disorder.
    Wilens TE
    Drugs; 2003; 63(22):2395-411. PubMed ID: 14609347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Spencer TJ; Biederman J
    J Atten Disord; 2002 Mar; 5(4):189-202. PubMed ID: 11967475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.
    Wilens TE; Morrison NR; Prince J
    Expert Rev Neurother; 2011 Oct; 11(10):1443-65. PubMed ID: 21955201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond methylphenidate: nonstimulant medications for youth with ADHD.
    Wood JG; Crager JL; Delap CM; Heiskell KD
    J Atten Disord; 2007 Nov; 11(3):341-50. PubMed ID: 17932386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of ADHD in adults.
    Adler LA; Chua HC
    J Clin Psychiatry; 2002; 63 Suppl 12():29-35. PubMed ID: 12562059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
    Slatkoff J; Greenfield B
    Expert Opin Investig Drugs; 2006 Jun; 15(6):649-67. PubMed ID: 16732717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review.
    Wilens TE; Biederman J; Spencer TJ; Prince J
    J Clin Psychopharmacol; 1995 Aug; 15(4):270-9. PubMed ID: 7593710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Hammerness PG; Biederman J; Kwon A; Spencer TJ; Clark S; Scott M; Podolski A; Ditterline JW; Morris MC; Moore H
    J Clin Psychiatry; 2005 Feb; 66(2):253-9. PubMed ID: 15705013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
    Waxmonsky JG
    Essent Psychopharmacol; 2005; 6(5):262-76. PubMed ID: 16222911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.